Cambridge Tech Podcast

James Parton & Faye Holland

Your weekly tech news download from in and around Cambridge, plus in-depth conversations with the founders, innovators, and enablers within the Cambridge tech ecosystem. Published every week and hosted by James Parton and Faye Holland. Get in touch with the show via info@cambridgetechpodcast.com Hosted on Acast. See acast.com/privacy for more information.

  1. Open source office productivity and how Collabora is leading the charge

    MAR 31

    Open source office productivity and how Collabora is leading the charge

    Michael Meeks joins us the week to talk about competing with Microsoft, and why Open Source Wins. Some of the highlights of our conversation include: On organic growth: "Unlike many VC-backed companies, we're organic, we're profitable and we have a mission which is to drive open source."The business model is counterintuitive but brilliant. By giving away free software, Collabora builds massive brand recognition and deployment. Users try it at home, fall in love with it, and when they need enterprise support, they know exactly who to call.On digital sovereignty: In an increasingly geopolitical world, Michael argues open source is the only path to true sovereignty. "The only way to have true digital sovereignty...is to use open source because then it is for the world. It is both local and a collaboration internationally."One of the most interesting technical insights: Collabora keeps documents on the server rather than downloading them to clients. This enables server-side policy enforcement - no copy-paste, no printing, no downloads, plus watermarking for traceability. Michael's remote-first approach is worth noting: rather than have some staff in an office and others remote (which creates two-tier communication), Collabora went fully distributed globally. They do maintain a Cambridge base with internships at Hills Road sixth form college, giving back to the community that shaped him. Whether you're a founder wrestling with funding strategy, a VC evaluating open source investments, or simply curious about how to build a profitable, mission-driven company without VC pressure, this episode delivers real insights. Ready to dive deeper? Download Collabora Office from your app store and listen to the full conversation on the Cambridge Tech Podcast. You'll leave thinking differently about competition, sovereignty, and what sustainable growth actually looks like. Headline sponsor Holden Polestar #CamTechPod Hosted on Acast. See acast.com/privacy for more information.

    28 min
  2. The Ryse Flow Story: Why Startups Must Go AI-Native

    MAR 17

    The Ryse Flow Story: Why Startups Must Go AI-Native

    The latest Cambridge Tech Podcast episode packed a punch with exciting announcements from the Cambridge ecosystem, followed by an in-depth conversation with Jean Michel Van, founder of Ryse Flow, a company building the next generation of AI-powered sales automation. The real gem of this episode is Jean Michel's journey from corporate product management to founding Ryse Flow. His story is refreshingly honest about the fears and decision-making that come with entrepreneurship. Jean Michel's background is unconventional. Born in Paris to parents who fled the Cambodian genocide, he spent 15 years in pharma and tech before making the leap to entrepreneurship. His early career in pharmaceutical finance eventually led him into tech through a pivotal acquisition role, where he discovered his passion for product management. After 15 years climbing the corporate ladder, Jean Michel reached a turning point. Rather than waiting for the ‘perfect idea’. he decided to take the leap. Ryse Flow's premise is compelling: AI won't simply be bolted onto existing software, it will fundamentally reshape how sales automation works. "AI is going to disrupt most of the legacy players in the market in the same way cloud disrupted client-server implementations in the early 2000s." Jean Michel's strategy is pragmatic: ·       Currently leveraging 70% existing tools while building proprietary IP ·       Only pursuing paid pilots - ensuring customer commitment and real feedback ·       Maintaining a lean, self-funded team to preserve long-term decision-making autonomy ·       Already profitable despite being early-stage This episode captures the real tension between corporate comfort and entrepreneurial ambition. Jean Michel's willingness to discuss both his fears and his conviction offers genuine insight for founders considering the leap. Tune in on your preferred podcast platform, and subscribe to join the weekly conversation. Headline sponsor Holden Polestar #CamTechPod Hosted on Acast. See acast.com/privacy for more information.

    39 min
  3. Cambridge's Next Generation of Deep Tech Innovators: Meet the #21toWatch Top21.2026

    MAR 10

    Cambridge's Next Generation of Deep Tech Innovators: Meet the #21toWatch Top21.2026

    Episode 182 features five of this year's #21toWatch winners - and if you're in the startup ecosystem, this one's unmissable. For those unfamiliar, for the last eight years #21toWatch has been high on the regions innovation showcase, and the numbers speak for themselves. Over eight cohorts, 168 companies have landed on the list and collectively raised a staggering £721 million. This year marks a particularly poignant milestone: its Faye's final year running the programme after creating it back in 2018. But we think you’ll agree, she's gone out with a bang. In this episode we talk to five of the winning companies: Cyclana Bio is tackling drug discovery from first principles, focusing on the extracellular matrix (the "biological dark matter" comprising 90% of your tissue). Lea Wenger explains how their multidisciplinary approach spanning Cambridge and Manchester is already attracting serious attention, with £5 million raised so far.Obasense is developing ultra-sensitive gas sensors for indoor air quality monitoring -particularly timely given the UK's new mould regulations. Founder, Osarenkhoe Ogbeide, is also building African mythology comics on the side!Myonerv is creating wearable neurostimulators for stroke rehabilitation. Sam Kourali's personal story - inspired by his cousin's stroke - drives a compelling business model targeting the US market's $60 billion opportunity.NANOPLUME just announced £2.2 million in funding for their bio-based aerogel thermal insulation. Three times more insulating than conventional materials, 60% lighter, and fully circular. Co-founder Tara Love says they're eyeing product launch within 18 months.Polytecks is mapping bioelectricity through flexible electrode arrays - starting with veterinary cardiology (dog heart disease affects over 80% of dogs) before moving to human diagnostics. Ruben Ruiz-Mateos Serrano tells us more. This episode captures something essential about where UK deep tech innovation is heading. These aren't incremental improvements - they're fundamental reimagining’s of how we solve problems in healthcare, climate tech, and industrial systems. Subscribe now and join the conversation. Because the next unicorn might just be one of these five. Headline sponsor Holden Polestar #CamTechPod Hosted on Acast. See acast.com/privacy for more information.

    50 min
  4. How Concr is Revolutionising Cancer Treatment Prediction

    FEB 17

    How Concr is Revolutionising Cancer Treatment Prediction

    Episode 179 hosts Faye Holland and James Parton sit down with Irina Barbina (CEO) and Matthew Griffiths (CTO) to unpick how Concr is using predictive modelling and digital twins to transform cancer drug development. Cancer data is fragmented. Clinical trials, pre-clinical research, and real-world patient data exist in silos. There's no unified way to predict how individual patients will respond to specific therapies, until now. Concr's technology borrows from astrophysics, specifically, how scientists model dark matter using gravitational lensing. The parallel is striking: Astrophysicists can't directly observe dark matter, so they build complex simulations to infer its distribution. Concr can't directly know why a drug worked for a patient, so they build digital twin simulations to predict outcomes. Key innovations: ·      Bayesian inference at scale to handle messy, incomplete cancer data ·      Hierarchical modelling that learns from shared biology across cancer types ·      94% prediction accuracy on retrospective clinical trial data ·      Prospective validation underway with NHS partners and pharma companies Concr dramatically reduces the cost and complexity of clinical trials. This episode brilliantly illustrates why Cambridge is a global innovation hub. It's not just about brilliant science, it's about brilliant people from different disciplines colliding, recognising patterns, and building companies that matter. Hosted on Acast. See acast.com/privacy for more information.

    32 min

About

Your weekly tech news download from in and around Cambridge, plus in-depth conversations with the founders, innovators, and enablers within the Cambridge tech ecosystem. Published every week and hosted by James Parton and Faye Holland. Get in touch with the show via info@cambridgetechpodcast.com Hosted on Acast. See acast.com/privacy for more information.

You Might Also Like